Related Experiment Video

Updated: Jul 30, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Cinnarizine in the treatment of chronic asthma

M B Emanuel, J A Chamberlain, S Whiting

    British Journal of Clinical Pharmacology
    |February 1, 1979
    PubMed

    More Related Videos

    A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion05:56

    A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

    Published on: May 12, 2023

    Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

    Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

    Published on: December 20, 2024

    Related Concept Videos

    Drugs Used in Lower Respiratory Disorders: Overview01:17

    Drugs Used in Lower Respiratory Disorders: Overview

    Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
    Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
    Antiasthma Drugs: Leukotriene Modifiers01:19

    Antiasthma Drugs: Leukotriene Modifiers

    Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
    Leukotriene modifiers work through two distinct mechanisms:
    Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

    Antiasthma Drugs: Muscarinic Receptor Antagonists

    Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
    Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
    Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

    Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

    Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
    ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
    Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

    Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

    Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
    Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
    Cystic Fibrosis: Management01:24

    Cystic Fibrosis: Management

    Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
    Sinus disease and chronic sinusitis...